Menopause drug Veozah approved by the FDA to treat hot flashes

  • The Food and Drug Administration has approved Veozah (fezolinetant), a drug to treat symptoms of menopause.
  • The drug, manufactured by Tokyo-headquartered Astellas Pharma, was found to significantly reduce hot flashes and night sweats that accompany menopause.
  • Veozah is considered an important development for menopause treatment because hormone therapy is not viable for all patients.

The Food and Drug Administration has approved a once-a-day pill to manage uncomfortable hot flashes caused by menopause.

The new drug, Veozah (fezolinetant), differs from the traditional treatment of increasing the hormones estrogen and progestin to reduce menopause symptoms, which include sweating, flushing and chills. Veozah, developed by Astellas Pharma, blocks a chemical in the brain called neurokinin B (NKB), which regulates body temperature.

“Hot flashes as a result of menopause can be a serious physical burden on women and affect their quality of life,”[ads1]; Janet Maynard, director of the FDA’s Office of Rare Diseases, Pediatrics, Urology and Reproductive Medicine, said in a statement. “The introduction of a new molecule to treat moderate to severe menopausal hot flashes will provide an additional safe and effective treatment option for women.”

Source link

Back to top button

mahjong slot